AstraZeneca begins development programme for BRILINTA reversal agent
MEDI2452 is being developed by MedImmune, AstraZeneca’s biologics research and development arm. Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.